210 related articles for article (PubMed ID: 29463533)
1. Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine.
Armitage EG; Alqaisi AQI; Godzien J; Peña I; Mbekeani AJ; Alonso-Herranz V; López-Gonzálvez Á; Martín J; Gabarro R; Denny PW; Barrett MP; Barbas C
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463533
[TBL] [Abstract][Full Text] [Related]
2. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
[TBL] [Abstract][Full Text] [Related]
3. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM
J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205
[TBL] [Abstract][Full Text] [Related]
4. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Imbert L; Ramos RG; Libong D; Abreu S; Loiseau PM; Chaminade P
Anal Bioanal Chem; 2012 Jan; 402(3):1169-82. PubMed ID: 22065347
[TBL] [Abstract][Full Text] [Related]
5. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
[TBL] [Abstract][Full Text] [Related]
6. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
7. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
9. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Rakotomanga M; Blanc S; Gaudin K; Chaminade P; Loiseau PM
Antimicrob Agents Chemother; 2007 Apr; 51(4):1425-30. PubMed ID: 17242145
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca
Pinto-Martinez AK; Rodriguez-Durán J; Serrano-Martin X; Hernandez-Rodriguez V; Benaim G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061745
[No Abstract] [Full Text] [Related]
11. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
12. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
14. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
16. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão JQ; Pita Pedro DP; Coelho AC
Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
[TBL] [Abstract][Full Text] [Related]
17. Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.
Pandharkar T; Zhu X; Mathur R; Jiang J; Schmittgen TD; Shaha C; Werbovetz KA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4682-9. PubMed ID: 24890590
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
[TBL] [Abstract][Full Text] [Related]
20. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
